IFP Advisors
ARCT icon

IFP Advisors’s Arcturus Therapeutics ARCT Stock Holding History

IFP Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.86K Sell
355
-229
-39% -$2.39K ﹤0.01% 3834
2026
Q2 		$3.92K Buy
584
+555
+1,914% +$4.38K ﹤0.01% 3920
2026
Q1 		$224 Buy
29
+25
+625% +$182 ﹤0.01% 4600
2025
Q4 		$25 Buy
+4
New +$43 ﹤0.01% 4779
2025
Q2 		– Hold
0
– – – 3953
2025
Q1 		– Hold
0
– – – 3940
2024
Q4 		– Hold
0
– – – 3969
2021
Q3 		– Sell
-591
Closed -$19K – 3368
2021
Q2 		$19K Buy
591
+402
+213% +$13.6K ﹤0.01% 1947
2021
Q1 		$9K Buy
189
+23
+14% +$1.37K ﹤0.01% 2160
2020
Q4 		$8K Buy
166
+6
+4% +$406 ﹤0.01% 2135
2020
Q3 		$6K Buy
+160
New +$7.94K ﹤0.01% 2080
2016
Q1 		– Sell
-214
Closed -$9K – 2405
2015
Q4 		$9K Buy
+214
New +$9.6K ﹤0.01% 2617

Other funds holding ARCT

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

IFP Advisors's ARCT Position: Q3 2026 in Review

IFP Advisors reduced its Arcturus Therapeutics (ARCT) stake by 39% in Q3 2026, selling an estimated $2.39K and leaving 355 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

IFP Advisors first reported a position in ARCT in Q4 2015 and has held it in 9 quarters since. The position peaked at $19K in Q2 2021. 101 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • IFP Advisors held 355 shares of Arcturus Therapeutics worth $4.86K as of Q3 2026.
  • IFP Advisors sold 229 Arcturus Therapeutics shares in Q3 2026, an estimated $2.39K.
  • Arcturus Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3834 holding.
  • IFP Advisors first reported a position in Arcturus Therapeutics in Q4 2015 and has held it in 9 quarters since.
  • IFP Advisors's Arcturus Therapeutics position peaked at $19K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.